PEOPLE - Oxford Immunotec makes appointment:
This article was originally published in Clinica
UK diagnostics company Oxford Immunotec (Abingdon, Oxfordshire) has appointed Ian Miscampbell as CFO. Previously, Mr Miscampbell was finance director of UK vaccine firm Microscience Holdings, (taken over by US-based therapeutic products firm Emergent BioSolutions in June this year). CEO Dr Peter Wrighton-Smith said the company would draw on Mr Miscampbell's expertise in several fields, including strategy development and fundraising in public and private markets.
You may also be interested in...
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake – but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.